NME1 and breast carcinoma: It will also be important to treat other breast cancer cell lines as well as primary human breast cancer cells, which might express larger amounts of anthrax toxin receptors than the MDA-MB-231 cells, with PA63 plus His6-NDPKA or LFN-NDPK-A to investigate whether these cells show enhanced sensitivity towards this system.